Folia Microbiologica

, Volume 51, Issue 5, pp 507–510 | Cite as

Probiotics manipulate host cytokine response and induce antimicrobial peptides

  • I. Trebichavský
  • I. Šplíchal
Brief Report


Probiotics modulate production of both cytokine and antimicrobial peptides. This effect can be regarded as a part of complex interplay between them and the host.


Lactobacillus Irritable Bowel Syndrome Antimicrobial Peptide Probiotic Strain Bifidobacterium Bifidum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



human β-defensin 2


interferon γ




transforming growth factor β


Toll-like receptor


tumor necrosis factor α


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bambou J.C., Giraud A., Menard S., Begue B., Rakatobe S., Heyman M., Taddei F., Cerf-ensussan N., Gaboriau-Routhiau V.:In vitro andex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensalEscherichia coli strain.J.Biol.Chem.279, 42984–42992 (2004).PubMedCrossRefGoogle Scholar
  2. Brousserd E.K., Surawicz C.M.: Probiotics and prebiotics in clinical practice.Nutr.Clin.Care7, 104–113 (2004).Google Scholar
  3. Bujňáková D., Vlková E., Rada V., Kmeť V.: Aggregation of lactobacilli and bifidobacteria withEscherichia coli O157.Folia Microbiol.49, 143–146 (2004).CrossRefGoogle Scholar
  4. Chen C.C., Louie S., Shi H.N., Walker W.A.: Preinoculation with the probioticLactobacillus acidophilus early in life effectively inhibits murineCitrobacter rodentium colitis.Pediatr.Res.58, 1185–1191 (2005).PubMedCrossRefGoogle Scholar
  5. Cross M.L., Ganner A., Teilab D., Fray L.M.: Patterns of cytokine induction by Gram-positive and Gram-negative probiotic bacteria.FEMS Immunol.Med.Microbiol.42, 173–180 (2004).PubMedCrossRefGoogle Scholar
  6. Cukrowska B., Lodinová-Žádníková R., Enders C., Sonnenborn U., Schulze J., Tlaskalova-Hogenová H.: Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probioticE. coli strain Nissle 1917.Scand.J.Immunol.55, 204–209 (2002).PubMedCrossRefGoogle Scholar
  7. Di Caro S., Tao H., Grillo A., Elia C., Gasbarrini G., Sepulveda A.R., Gasbarrini A.: Effect ofLactobacillus GG on genes expression pattern in small bowel mucosa.Dig.Liver Dis.37, 320–329 (2005).PubMedCrossRefGoogle Scholar
  8. Di Giacinto C., Marinaro M., Sanchez M., Strober W., Boirivant M.: Probiotics ameliorate recurrent TH1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells.J.Immunol.174, 3237–3246 (2005).PubMedGoogle Scholar
  9. Dotan I., Rachmilewitz D.: Probiotics in inflammatory bowel disease: possible mechanisms of action.Curr.Opin.Gastroenterol.21, 426–430 (2005).PubMedGoogle Scholar
  10. Floch M.H.: Probiotics, irritable bowel syndrome, and inflammatory bowel disease.Curr.Treat.Options Gastroenterol.6, 283–288 (2003).PubMedCrossRefGoogle Scholar
  11. Gorbach S.L.: Probiotics and gastrointestinal health.Am.J.Gastroenterol.95 (Suppl. 1), S2-S4 (2000).PubMedCrossRefGoogle Scholar
  12. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., Kamm M.A., Knight S.C., Stagg A.J.: Modulation of human dendritic cell phenotype and function by probiotic bacteria.Gut53, 1602–1609 (2004).PubMedCrossRefGoogle Scholar
  13. Hockertz S.: Augmentation of host defense against bacteria and fungal infections of mice pretreated with the non-pathogenicEscherichia coli strain Nissle 1917.Arzeimittelforschung47, 793–796 (1991).Google Scholar
  14. Kalliomaki M., Salminen S., Poussa T., Arvilommi H., Isolauri E.: Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial.Lancet361, 1869–1871 (2003).PubMedCrossRefGoogle Scholar
  15. Kozáková H., Řeháková Z., Kolínská J.:Bifidobacterium bifidum monoassociation of gnotobiotic mice: effect on enterocyte brushborder enzymes.Folia Microbiol.46, 573–576 (2001).CrossRefGoogle Scholar
  16. Krammer H.J., Schlieger F., Harder H., Franke A., Singer M.V.: Probiotics as therapeutic agents in irritable bowel syndrome.Z.Gastroenterol.43, 467–471 (2005).PubMedCrossRefGoogle Scholar
  17. Kruis W., Frič P., Pokrotnieks J., Lukaš M., Fixa B., Kaščák M., Kamm M.A., Weismueller J., Beglinger C., Stolte M., Wolff C., Schulze J.: Maintaining remission of ulcerative colitis with the probioticEscherichia coli Nissle 1917 is as effective as with standard mesalazine.Gut53, 1617–1623 (2004).PubMedCrossRefGoogle Scholar
  18. Lammers K.M., Helwig U., Swennen E., Rizzello F., Venturi A., Caramelli E., Kamm M.A., Brigidi P., Gionchetti P., Campieri M.: Effect of probiotic strains on interleukin 8 production by HT29/19A cells.Am.J.Gastroenterol.97, 1182–1186 (2002).PubMedCrossRefGoogle Scholar
  19. Lilly D.M., Stillwell R.H.: Probiotics: grown promoting substances produced by microorganisms.Science147, 747–748 (1965).PubMedCrossRefGoogle Scholar
  20. Lodinová-Žadniková R., Sonnenborn U.: Effect of preventive administration of a nonpathogenicEscherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants.Biol.Neonate71, 224–232 (1997).PubMedCrossRefGoogle Scholar
  21. Lodinová-Žadniková R., Sonnenborn U., Tlaskalová H.: Probiotics andE. coli infections in man.Vet.Quart.20 (Suppl. 3), S78-S81 (1998).Google Scholar
  22. Lodinová-Žadníková R., Cukrowska B., Tlaskalová-Hogenová H.: Oral administration of probioticEscherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years).Internat.Arch.Allergy Immunol.131, 209–211 (2003).CrossRefGoogle Scholar
  23. Mandel L., Trebichavsky I., Šplíchal I., Schulze J.: Stimulation of intestinal immune cells byE. coli in gnotobiotic piglets, pp. 463–464 inAdvances in Mucosal Immunology (J. Mestecky, M.W. Rusell, S. Jackson, S.M. Michalek, H. Tlaskalová-Hogenová, J. Šterzl, Eds). Plenum Press, New York-London 1995.Google Scholar
  24. Mattar M.A., Cortinas T.I., De Guzman A.M.: Immunogenic protein variations ofClostridium chauvoei cellular antigens associated with the culture growth phase.FEMS Immunol.Med.Microbiol.33, 9–14 (2002).PubMedCrossRefGoogle Scholar
  25. Mego M., Majek J., Končeková R., Ebringer L., Čierniková S., Rauko P., Kovač M., Trupl J., Slezák P., Zajac V.: Intramucosal bacteria in colon cancer and their elimination by probiotic strainEnterococcus faecium M-74 with organic selenium.Folia Microbiol.50, 443–447 (2005).CrossRefGoogle Scholar
  26. Metchnikoff E.: Lactic acid as inhibiting intestinal putrefaction, pp. 161–183 inThe Prolongation of Life: Optimistic Studies (P. Chalmers Mitchell, Ed.) Heinemann, London 1907.Google Scholar
  27. Mlčková P., Čechová D., Marušková L., Chalupná P., Novotná O., Prokešová L.: Role of T cells in the adjuvant effect ofBacillus firmus on the immune system of mice: intranasal and intratracheal immunization study with ovalbumin.Folia Microbiol.48, 427–434 (2003).CrossRefGoogle Scholar
  28. Mlčková P., Poláček M., Čechová D., Marušková L., Staňková I., Chalupná P., Novotná O., Julák J., Prokešová L.: Intratracheal and intranasal immunization with ovalbumin conjugated withBacillus firmus as a carrier in mice.Folia Microbiol.50, 247–254 (2005).CrossRefGoogle Scholar
  29. Niers L.E., Timmerman H.M., Rijkers G.T., van Bleek G.M., van Uden N.O., Knol E.F., Kapsenberg M.L., Kimpen J.L., Hoekstra M.O.: Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines.Clin.Exp.Allergy35, 1481–1489 (2005).PubMedCrossRefGoogle Scholar
  30. Nissle A.: Die antagonistische Behandlung chronischer Darmstorungen mit Colibacterien.Med.Klinik2, 29–30 (1918).Google Scholar
  31. O’Mahony L., O’Callaghan L., McCarthy J., Shilling D., Scully P., Sibartie S., Kavanagh E., Kirwan W.O., Redmond H.P., Collins J.K., Shanahan F.: Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans.Am.J.Physiol.Gastrointest.Liver Physiol.290, G839-G845 (2006).PubMedCrossRefGoogle Scholar
  32. Otte J.M., Rosenberg I.M., Podolsky D.K.: Intestinal myofibroblasts in innate immune responses of the intestine.Gastroenterology124, 1866–1878 (2003).PubMedCrossRefGoogle Scholar
  33. Petrof E.O., Kojima K., Ropeleski M.J., Musch M.W., Tao Y., De S.C., Chang E.B.: Probiotics inhibit nuclear factor κB and induce heat-shock proteins in colonic epithelial cells through proteasome inhibition.Gastroenterology127, 1474–1487 (2004).PubMedCrossRefGoogle Scholar
  34. Prokešová L., Mlčková P., Staňková I., Ladmanová P., Ježková J., Chalupná P., Novotná O., Čechová D., Julák J.: Immunostimulatory effect ofBacillus firmus on mouse lymphocytes.Folia Microbiol.47, 193–197 (2002).CrossRefGoogle Scholar
  35. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., Raz E.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probictics in murine experimental colitis.Gastroenterology126, 520–528 (2004).PubMedCrossRefGoogle Scholar
  36. Rovenský J., Švík K., Stančíková M., Istok R., Ebringer L., Ferenčík M.: Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilizedEnterococcus faecium enriched with organic selenium.Folia Microbiol.47, 573–578 (2002).CrossRefGoogle Scholar
  37. Sartor R.B.: Probiotic therapy of intestinal inflammation and infections.Curr.Opin.Gastroenterol.21, 44–50 (2005).PubMedGoogle Scholar
  38. Schultz M., Strauch U.G., Linde H.J., Watzl S., Obermaier F., Gottl C., Dunger N., Grunwald N., Scholmerich J., Rath H.C.: Preventive effects ofEscherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.Clin.Diagn.Lab.Immunol.11, 372–378 (2004).PubMedCrossRefGoogle Scholar
  39. Seifert H.S., Gessler F.: Oral long-term administration of probioticB. cereus — an alternative for the prevention of enterotoxemia.Deutsch.Tierarztl.Wochenschr.103, 386–389 (1996).Google Scholar
  40. Senok A.C., Ismaeel A.Y., Botta G.A.: Probiotics: facts and myths.Clin.Microbiol.Infect.11, 958–966 (2005).PubMedCrossRefGoogle Scholar
  41. Sima P., Trebichavský I., Sigler K.: Mammalian antibiotic peptides.Folia Microbiol.48, 123–137 (2003a).CrossRefGoogle Scholar
  42. Šíma P., Trebichavský I., Sigler K.: Nonmammalian vertebrate antibiotic peptides.Folia Microbiol.48, 709–724 (2003b).CrossRefGoogle Scholar
  43. Šplíchal I., Fagerhol M.K., Trebichavský I., Šplíchalová A., Schulze J.: The effect of intestinal colonization of germ-free pigs withEscherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages.Immunobiology209, 681–687 (2005a).PubMedCrossRefGoogle Scholar
  44. Šplíchal I., Trebichavský I., Šplíchalová A., Barrow P.A.: Protection of gnotobiotic pigs againstSalmonella enterica serotype Typhimurium by rough mutant of the same serotype is accompanied by the change of local and systemic cytokine response.Vet.Immunol.Immunopathol.103, 155–161 (2005b).PubMedCrossRefGoogle Scholar
  45. Stříž I., Trebichavský I.: Calprotectin — a pleiotropic molecule in acute and chronic inflammation.Physiol.Res.53, 245–253 (2004).PubMedGoogle Scholar
  46. Strompfová V., Lauková A., Ouwehand A.C.: Lactobacilli and enterococci — potential probiotics for dogs.Folia Microbiol.49, 203–208 (2004).CrossRefGoogle Scholar
  47. Sturm A., Rilling K., Baumgart D.C., Gargas K., Bou-Ghazale T., Raupach B., Eckert J., Schumann R.R., Enders C., Sonnenborn U., Wiedenmann B., Dignass A.U.:Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansionvia toll-like receptor 2 signaling.Infect.Immun.73, 1452–1465 (2005).PubMedCrossRefGoogle Scholar
  48. Varrala O.: Immunological effects of probiotics with special reference to lactobacilli.Clin.Exp.Allergy33, 1634–1640 (2003).CrossRefGoogle Scholar
  49. van der Waaij D.: The role of microbial flora in the development, maintenance and modulation of the immune function.Adv.Physiol.Sci.29, 443–477 (1980).Google Scholar
  50. Wehkamp J., Hardes J., Wehkamp K., Wehkamp-von Meissner B., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., Schroder J.M., Stange E.F.: NF-κB- and AP-1-mediated induction of human β-defensin-2 in intestinal epithelial cells byEscherichia coli Nissle 1917: a novel effect of a probiotic bacterium.Infect.Immun.72, 5750–5758 (2004).PubMedCrossRefGoogle Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic 2006

Authors and Affiliations

  • I. Trebichavský
    • 1
  • I. Šplíchal
    • 1
  1. 1.Division of Immunology and Gnotobiology, Institute of MicrobiologyAcademy of Sciences of the Czech RepublicNový HrádekCzechia

Personalised recommendations